Article

Arzerra Fails in Phase 3 Trial for B-cell Lymphoma

GSK/GenMab's monoclonal antibody, Azerra, failed to improve PFS over a rituxan/chemotherapy combination in patients with relapsed/refractory diffuse large B-cell lymphoma.

GlaxoSmithKline/Genmab's leukaemia drug ofatumumab (marketed as Arzerra) has hit a setback after failing to meet targets in a late-stage trial assessing its potential in patients with B-cell lymphoma.

GSK said it is now unlikely that ofatumumab will be filed for this indication, given that a combination of the drug plus chemotherapy failed to outperform a rituxan/chemotherapy combo on progression free survival in patients with relapsed/refractory diffuse large B-cell lymphoma, the most common form of non-Hodgkin lymphoma (NHL).

Read the report here: http://bit.ly/1j5bSXD

Source: PharmaTimes online

Related Videos
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
dr joseph alvarnas
dr joseph alvarnas
Related Content
FDA approval. | Image Credit: syahrir - stock.adobe.com
November 21st 2024

FDA Approves Zanidatamab-hrii for HER2+ Biliary Tract Cancer

Cameron Santoro
Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.
managed care cast logo
October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Kasey Bond, MPH, Perlmutter Cancer Center
November 17th 2024

Uniting to Support Patients With Cancer Beyond Treatment

Maggie L. Shaw
Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Managed Care Cast logo
April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Oscar B. Lahoud, MD, NYU Langone Health
November 13th 2024

Bridging Cancer Care Gaps and Overcoming Medical Mistrust

Maggie L. Shaw
In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
AJMC
November 13th 2024

How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care

Arthur S. Hong, MD, MPH Beverly Kyalwazi, MD Ethan A. Halm, MD, MPH, MBA D. Mark Courtney, MD, MSCI John W. Sweetenham, MD Navid Sadeghi, MD, MSPH John V. Cox, DO, MBA Simon J. Craddock Lee, PhD, MPH
Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo